Work

Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors

Year: 2011

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-011-9742-1

Authors: Alan H. Bryce, Ravi Rao, Jann Sarkaria, Joel M. Reid, Yingwei Qi, Rui Qin, C. David James, Robert B. Jenkins, Joseph Boni, Charles Erlichman, Paul Haluska

Institutions: Mayo Clinic, Mayo Clinic in Arizona, Saint Agnes Medical Center, University of California, San Francisco, Pfizer (United States)

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: U.S. Public Health Service, National Cancer Institute

Awards: G7114658202, Phase I Clinical Trials of Anticancer Agents, Mayo SPORE in Brain Cancer, G8707282179, Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic, G932523968

OpenAlex ID: W1985937921

FWCI: 1.946

Cites: 23

Cited by: 33

Related to: 10